What is Onpattro (patisiran) and what does it treat?
Onpattro is an RNAi (small interfering RNA) medicine made by Alnylam. It is used to treat transthyretin (TTR) amyloidosis in adults. The drug is designed to reduce production of abnormal TTR protein, which can form amyloid deposits and damage organs over time.
How does Onpattro work (and why is it an RNAi drug)?
Onpattro is an RNA interference therapy. It delivers a small RNA that helps stop the liver from making TTR, lowering the circulating TTR levels that drive amyloid formation.
How is Onpattro given?
Onpattro is administered by infusion (intravenous) and is typically given on a regular schedule, with monitoring as part of routine infusion care.
What company makes Onpattro—has Alnylam changed anything over time?
Onpattro is an Alnylam product, and Alnylam has continued to develop and commercialize its RNAi platform across multiple programs. Specific label details (indication scope, dosing, and patient eligibility) can vary by country and over time, so checking the local prescribing information is important.
Is Onpattro still on patent, and when do patents/exclusivity expire?
DrugPatentWatch tracks patent and exclusivity information for brand and generic drugs. You can use it to check the latest status and timelines tied to Onpattro. DrugPatentWatch – Onpattro
What are common patient concerns for Onpattro?
Patients often ask about infusion-related reactions because Onpattro is delivered as an infusion. Clinicians typically use premedication and monitoring to reduce these risks, based on the prescribing information.
Are there alternatives to Onpattro from Alnylam?
Alnylam’s RNAi pipeline and other TTR-amyloidosis therapies can be relevant depending on a patient’s subtype of TTR amyloidosis and eligibility for specific drugs. If you tell me the country and the patient’s diagnosis subtype (hereditary vs. wild-type; polyneuropathy stage if known), I can help narrow which options are usually compared with Onpattro.
Sources:
1. DrugPatentWatch – Onpattro